William E. Brady, PhD

William E. Brady, PhD

Research Assistant Professor, Department of Biostatistics

Contact Information

RSC-422
Roswell Park Cancer Institute
Phone: 716-845-3803
Fax: 716-845-4860
Email: william.brady@roswellpark.org

 

Research Interests: Phase I and Phase II clinical trial designs in oncology; application of exact testing methods to binary and categorical data

Selected Publications

  • Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, Badmev V, Prey JD and Rustum YM.  A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of ironetecan in solid tumors.  Cancer chemotherapy and Pharmacology 2008; 62(3):499-508. PMID:  17989978
  • Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K Crispens MA, Resnick KE and Howell SB.  A phase II study of a urokinasae-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma:  A Gynecologic Oncology Group study.  Gynecologic Oncology 2012; 125(3):635-639.  PMCID:  PMC4370623
  • Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RD, Pathak HB, Hu W, Alpaugh RK, Sood AK and Godwin Ak.  Phase II evaluation of dasatinib in the treatment of recurrent or persistant epthelial ovarian or primary peritoneal carcinoma:  A Gynecologic Oncology Group Study.  Gynecologic Oncology 2012; 127(1):70-74.  PMCID:  PMC3748717
  • Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers W, Birrer M and GershensonDM.  Selumetinib in women with recurrent low-grade seriou carcinoma of the ovary or peritoneum:  an open-label, single-arm, pahse 2 study.  The Lancet Oncology 2013; 14(2):134-40.  PMCID:  PMC3627419
  • Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, De Geest K and Gershenson DM.  Efficac and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors:  results of a phase 2 trial of the Gynecologic Oncology Group.  Cancer 2014; 120(3):344-351.  PMCID:  PMC4250045
  • Ngamphaiboon N, DY GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding, Y, Brady W, Fetterly G and Adjei AA.  A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.  Invest New Drugs 2015; 33(1):225-232.  PMID:  25371323
  • Rosanski CH, Utley A, Carlson LM, Farren MR, Murray M, Russell LM, Nair JR, Yang Z, Brady W, Garrett-Sinha LA, Schoenberger SP, Green J< Boise LH and Lee KP.  CD28 Promotes Plasma Cell Survival Sustained Antibody Responses, and BLIMP-1 Upregulation through its Distal PYAP Proline Motif.  Jorunal of Immunology 2015; 194(10):4717-4728. PMCID:  PMC4416738